Clinical Trial Update: Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors

View source ↗

Summary

A completed study comparing TDTP-RECIST with RECIST 1.1 and other volumetric methods to evaluate therapeutic response in irregular malignant tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Gallbladder Cancer
• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma) | Status: COMPLETED